Cited by 399Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Komoroski, B, Vachharajani, N, Feng, Y, Li, L, Kornhauser, D, Pfister, M·2009·Clinical Pharmacology & Therapeutics

DOI 10.1038/clpt.2008.250

Open this paper in CoChat — free account

Abstract

Dapagliflozin, administered to patients in once-daily oral doses, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks the reabsorption of glucose from urine into the blood. This 14-day study randomized patients with type 2 diabetes mellitus (T2DM) to four treatment groups receiving daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin or placebo, in order to evaluate glucosuria and glycemic parameters. Significant reductions in fasting serum glucose (FSG) were observed on day 2 with 100 mg dapagliflozin (-9.3%, P < 0.001), and dose-dependent reductions were observed on day 13 with the 5-mg (-11.7%; P < 0.05), 25-mg (-13.3%; P < 0.05), and 100-mg (-21.8%; P < 0.0001) doses as compared with placebo. Significant improvements in oral glucose tolerance test (OGTT) were observed with all doses on days 2 and 13 (P < 0.001 as compared with placebo). On day 14, urine glucose values were 36.6, 70.1, and 69.9 g/day for the 5-, 25-, and 100-mg doses (as compared with no change for placebo), which were slightly lower than those on day 1. This was attributed to the decrease in filtered glucose load following improved glycemic control. Dapagliflozin produced dose-dependent increases in glucosuria and clinically meaningful changes in glycemic parameters in T2DM patients.

Integrity signals

Registry

Crossref · 10.1038/clpt.2008.250

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
Rossetti, L., Smith, D. J., Shulman, G. I., Papachristou, D. N., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 824
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., & Whaley, J. M. (2008) · Diabetes · doi:10.2337/db07-1472 · Cited by 423
Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria
Santer, R., Kinner, M., Lassen, C. L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., Daschner, M., Ehrich, J. H. H., Kemper, M., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092790.89332.d2 · Cited by 304
Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level
Katsuno, K., Fujimori, Y., Takemura, Y., Hiratochi, M., Itoh, F., Komatsu, Y., Fujikura, H., & Isaji, M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110296 · Cited by 268
Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal
Andrews, W. J., Vasquez, B., NAGULESPARAN, M., Klimeś, I., Foley, J. E., Unger, R. H., & Reaven, G. M. (1984) · Diabetes · doi:10.2337/diab.33.7.634 · Cited by 194
Candidal Vulvovaginitis
Sobel, J. D. (1993) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-199303000-00021 · Cited by 154
Long-term outcome of renal glucosuria type 0: the original patient and his natural history
Scholl‐Bürgi, S., Santer, R., & Ehrich, J. H. H. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh366 · Cited by 104

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 3

Chen J, 2008, Diabetes, 57, A682
Oemar B.S, 1987, Clin. Nephrol, 27, 156
Gibb D, 1995, NZ Med. J, 108, 252

Sorted by citations

Items 201–300 of 399

SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem
Jabbour, S. A. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.01.2731 · Cited by 26
SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 25
The role of kidney in glucose homeostasis – SGLT2 inhibitors, a new approach in diabetes treatment
Andrianesis, V., & Doupis, J. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.827399 · Cited by 25
Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus
Bando, Y., Tohyama, H., Aoki, K., Kanehara, H., Hisada, A., Okafuji, K., & Toya, D. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.06.001 · Cited by 23
Kidney in Diabetes: from Organ Damage Target to Therapeutic Target
Salvatore, T., Carbonara, O., Cozzolino, D., Torella, R., Nasti, R., Lascar, N., & Sasso, F. C. (2011) · Current Drug Metabolism · doi:10.2174/138920011796504509 · Cited by 24
COVID-19 pneumonia in lung transplant recipients: Report of 2 cases
Cozzi, E., Faccioli, E., Marinello, S., Loy, M., Congedi, S., Calabrese, F., Romagnoli, M., Cattelan, A. M., & Rea, F. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15993 · Cited by 23
Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus
Tang, W., Leil, T. A., JOHNSSON, E. K., Boulton, D. W., & LaCreta, F. P. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12594 · Cited by 23
Novel therapeutics and targets for the treatment of diabetes
Aicher, T. D., Boyd, S. A., McVean, M., & Celeste, A. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.1 · Cited by 21
SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis
Wang, M., Liu, X., Ding, B., Lu, Q., & Ma, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116994 · Cited by 22
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 52
SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases
Checa-Ros, A., Okojie, O.-J., & D’Marco, L. (2025) · Metabolites · doi:10.3390/metabo15080536 · Cited by 23
Sodium–glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials
Kipnes, M. S. (2011) · Clinical Investigation · doi:10.4155/cli.10.12 · Cited by 21
Dapagliflozin: Clinical practice compared with pre-registration trial data
McGovern, A. P., Dutta, N., Munro, N. M., Watters, K., & Feher, M. D. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.047 · Cited by 21
Empagliflozin and Dapagliflozin Increase Na+ and Inward Rectifier K+ Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs)
Dago, M., Crespo‐García, T., Cámara‐Checa, A., Rapún, J., Rubio‐Alarcón, M., Marín, M., Tamargo, J. L., Caballero, R., & Delpón, E. (2022) · Cells · doi:10.3390/cells11233707 · Cited by 21
SGLT Inhibitors: a Novel Target for Diabetes
Kanwal, A., & Banerjee, S. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.78 · Cited by 22
Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
van Raalte, D. H., & Bjornstad, P. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz228 · Cited by 23
Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis
Yu, H., Basu, S., & Hallow, K. M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008074 · Cited by 22
Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus
Yong, X., Wen, A., Liu, X., Liu, H., Liu, Y.-P., Li, N., Hu, T., Chen, Y., Wang, M., Wang, L., et al. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0366-7 · Cited by 21
Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus—A Narrative Review
Brata, R. D., Paşcalău, A. V., Frățilă, O., Paul, I. L., Muresan, M. M., Cămărășan, A., & Ilias, T. I. (2024) · Healthcare · doi:10.3390/healthcare12232464 · Cited by 21
Identification of phlorizin binding domains in sodium-glucose cotransporter family: SGLT1 as a unique model system
Raja, M., & Kinne, R. K.-H. (2015) · Biochimie · doi:10.1016/j.biochi.2015.06.003 · Cited by 20
Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin
Woo, V. C., Berard, L., BAJAJ, H. S., Ékoé, J.-M., & Senior, P. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.01.009 · Cited by 21
Conformationally Constrained Spiro C‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) Inhibitors
Lv, B., Feng, Y., Dong, J., Xu, M., Xu, B., Zhang, W., Sheng, Z., Welihinda, A. A., Seed, B., & Chen, Y. (2010) · ChemMedChem · doi:10.1002/cmdc.201000051 · Cited by 21
Self-citation
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Imamura, A., Kusunoki, M., Ueda, S., Hayashi, N., & Imai, Y. (2013) · Diabetes Therapy · doi:10.1007/s13300-012-0016-5 · Cited by 19
Clinical implication of SGLT2 inhibitors in type 2 diabetes
Kim, G. W., & Chung, S. H. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0419-0 · Cited by 19
Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia
Durcan, E., Özkan, S., Saygı, H. İ., Dinçer, M. T., Korkmaz, Ö. P., Şahin, S., Karaca, C., Sulu, C., Bakır, A., Özkaya, H. M., et al. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13261 · Cited by 18
A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition
Basile, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2302 · Cited by 18
Dapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 19
Sodium-dependent glucose transporter protein as a potential therapeutic target for improving glycemic control in diabetes
Castaneda‐Sceppa, C., & Castañeda, F. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00423.x · Cited by 19
The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
Huang, Y., Lu, W., & Lu, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00815-y · Cited by 17
Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, in patients with type 2 diabetes
Riggs, M. M., SEMAN, L. J., Staab, A., MacGregor, T. R., Gillespie, W. R., Gastonguay, M. R., Woerle, H. J., & Macha, S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12453 · Cited by 18
A Review of Therapeutic Strategies against Cardiac Fibrosis: From Classical Pharmacology to Novel Molecular, Epigenetic, and Biotechnological Approaches
Floris, E., Cozzolino, C., Marconi, S., Tonicello, F., Picchio, V., Pagano, F., & Chimenti, I. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2408226 · Cited by 18
Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time
Parikh, S. J., Wilding, J. P. H., Jabbour, S. A., & Hardy, E. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12531 · Cited by 16
Expansion of the Homeostasis Model Assessment of β-Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2. Diabetes Care 2013;36:2324–2330
Hill, N. R., Lévy, J., & Matthews, D. R. (2014) · Diabetes Care · doi:10.2337/dc14-er09a · Cited by 16
Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin
Jabbour, S. A., Whaley, J. M., Tirmenstein, M. A., Poucher, S. M., Reilly, T. P., Boulton, D. W., Saye, J. A., List, J. F., & Parikh, S. J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2569 · Cited by 15
A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
Fadini, G. P., Tentolouris, N., Mateos, I. C., Bellido, V., & Morales, C. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00744-6 · Cited by 15
Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
Demin, O. O., Yakovleva, T. A., Kolobkov, D., & Demin, O. O. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00218 · Cited by 15
Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
Du, X., Lizarzaburu, M. E., Turcotte, S., Lee, T. W., Greenberg, J., Shan, B., Fan, P. W., Ling, Y., Medina, J. C., & Houze, J. B. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.053 · Cited by 16
Dapagliflozin: an emerging treatment option in type 2 diabetes
Kipnes, M. S. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766794 · Cited by 15
The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance
Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L., Li, Y., Yuan, X., Xu, D., & Zhou, L. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s399367 · Cited by 17
Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
Rajesh, R., Patel, N. B., Vidyasagar, S., Unnikrishnan, M. K., Pandey, S., Varghese, M., & Gang, S. (2010) · Cited by 13
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
Chao, E. C. (2012) · Core evidence · doi:10.2147/ce.s16359 · Cited by 14
From history to reality: sodium glucose co‐transporter 2 inhibitors – a novel therapy for type 2 diabetes mellitus
Nair, S., Joseph, F., Ewins, D. L., Wilding, J. P. H., & Goenka, N. (2010) · Practical Diabetes · doi:10.1002/pdi.1509 · Cited by 14
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Pancholia, A. K. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.08.022 · Cited by 16
Pharmacotherapy of hyperglycemia
Kulasa, K. M., & Henry, R. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903196758 · Cited by 13
Insulin dependent and independent normalization of blood glucose levels reduces the enhanced rewarding effects of nicotine in a rodent model of diabetes
Íbias, J., O’Dell, L. E., & Nazarian, A. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.018 · Cited by 14
Tofogliflozin: the road goes ever on
Pafili, K., & Παπάνας, Ν. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.916278 · Cited by 13
End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
Fediuk, D. J., Nucci, G., Dawra, V. K., Callegari, E., Zhou, S., Musante, C. J., Liang, Y., Sweeney, K., & Sahasrabudhe, V. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12633 · Cited by 12
Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis
Wang, Y., Shao, X., & Liu, Z. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0616 · Cited by 13
SGLT2 : A Potential Target for the Pharmacogenetics of Type 2 Diabetes?
Tönjes, A., & Kovacs, P. L. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.61 · Cited by 13
Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2/HO-1/GPX4 signaling pathway
Zhang, J., Chen, X., Lv, S., & Hao, Q. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317295 · Cited by 12
Physicochemical characterization of dapagliflozin and its solid-state behavior in stress stability test
Oh, D., Chon, J., Kang, J., Han, C., Shin, D. H., Kim, J. Y., Rhee, Y.-S., Chun, M.-H., Kim, D., & Park, C. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2021.1908333 · Cited by 12
The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials
Zhai, M., Du, X., Changmei, L., & Xu, H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.703937 · Cited by 12
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck, M. A., Prato, S. D., Meier, J. J., Durán-Garcia, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2013) · PubMed · doi:10.1055/s-0032-1305283 · Cited by 12
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease
Milder, T. Y., STOCKER, S. L., Samocha‐Bonet, D., Day, R. O., & Greenfield, J. R. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02732-y · Cited by 13
Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
Koomen, J. V., Stevens, J., & Heerspink, H. J. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14318 · Cited by 12
Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin
Ganorkar, S. B., Sharma, S. S., Patil, M. R., Bobade, P. S., Dhote, A. M., & Shirkhedkar, A. A. (2020) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2020.1777524 · Cited by 12
Drug Transporters: Recent Advances and Therapeutic Applications
Franke, R. M., & Sparreboom, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.239 · Cited by 12
Recent and Emerging Therapeutic Medications in Type 2 Diabetes Mellitus
Lo, M. C., & Lansang, M. C. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ec9eb2 · Cited by 12
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
Yu, H. J., & Woo, V. C. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s117982 · Cited by 12
Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention
Imai, T., Akimoto, T., Ito, C., Masuda, T., & Nagata, D. (2015) · Drug Target Insights · doi:10.4137/dti.s31710 · Cited by 12
Dapagliflozin attenuates high glucose-and hypoxia/reoxygenation-induced injury via activating AMPK/mTOR-OPA1-mediated mitochondrial autophagy in H9c2 cardiomyocytes
Tu, W., Li, L., Yi, M., Chen, J., Wang, X., & Sun, Y. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2023.2252200 · Cited by 11
Self-citation
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors—Fighting Diabetes from a New Perspective
Angelopoulos, T. P., & Doupis, J. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0127-7 · Cited by 12
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
Bailey, C. J., Prato, S. D., Wei, C., Reyner, D., & Saraiva, G. L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13841 · Cited by 11
A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
Brown, E. E., Wilton, M., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Burgess, M. I., Howarth, E., Umpleby, A. M., Kemp, G. J., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045663 · Cited by 12
Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome
Lin, B., Guo, X., Lü, W., Niu, R. L., Zeng, X., Chen, Z., Wu, C., & Liu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176742 · Cited by 10
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2
Gould, J. C., Kasichayanula, S., Shepperly, D. C., & Boulton, D. W. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2013.07.002 · Cited by 11
Exposure–response relationships for the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin with regard to renal risk markers
Kroonen, M. Y. A. M., Koomen, J. V., Petrykiv, S. I., Laverman, G. D., Heerspink, H. J. L., & Stevens, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13976 · Cited by 10
A model‐based approach to investigating the relationship between glucose‐insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes
Shah, M., Stolbov, L. A., Yakovleva, T. A., Tang, W., Sokolov, V., Penland, R. C., Boulton, D. W., & PARKINSON, J. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14305 · Cited by 11
Circulating complement‐1q tumor necrosis factor‐α‐related protein isoform 5 levels are low in type 2 diabetes patients and reduced by dapagliflozin
Zhang, C., Luo, Y., Liu, R., Li, X., Yang, M., Zhang, Y., Li, L., Mou, H., Guo, L., Li, J., et al. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13069 · Cited by 8
Self-citation
Sodium glucose co-transporter 2 inhibitors: A novel approach to the management of type 2 diabetes mellitus
Davis, C. S., Fleming, J. W., & Warrington, L. E. (2014) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12135 · Cited by 9
Case History
Washburn, W. N. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00023-7 · Cited by 9
The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins
Bodnar, P., Mazurkiewicz, M., Chwalba, T., Romuk, E. B., Ciszek-Chwalba, A., Jacheć, W., & Wojciechowska, C. (2023) · Biomedicines · doi:10.3390/biomedicines11082236 · Cited by 8
Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project)
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · JMIR Research Protocols · doi:10.2196/56067 · Cited by 7
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
Saitō, M., Kaibara, A., Kadokura, T., Toyoshima, J., Yoshida, S., Kazuta, K., & Ueyama, E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13972 · Cited by 8
Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure – Empire HF and SIMPLE
Emanuelsson, F., Jensen, J., Omar, M., Jürgens, M., Kistorp, C., Brandt, N., Møller, J. E., Schou, M., Bechmann, L. E., Larsen, E. L., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.015 · Cited by 8
The Kidney as a Treatment Target for Type 2 Diabetes
Dokken, B. B. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.1.29 · Cited by 7
Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study
Vakkalagadda, B. J., Lubin, S., Reynolds, L., Liang, D., Marion, A. S., LaCreta, F. P., & Boulton, D. W. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.005 · Cited by 7
Dapagliflozin for the treatment of type 1 diabetes mellitus
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1339788 · Cited by 7
The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis
Xu, X., Xu, W., Zhuo, Q., & Yan, Y. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-121 · Cited by 7
Effectiveness of Dapagliflozin as Add-On to Metformin with or without Other Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Database Study
Sethi, B. K., Sahay, R. K., TIWASKAR, M. H., Negalur, V. B., Dhediya, R., Gaurav, K., Rathod, R., Kotak, B., Dhanaki, G. D., & Shah, S. P. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00398-8 · Cited by 7
The kidneys as an emerging target for the treatment of diabetes mellitus: What we know, thought we knew and hope to gain
Ahmed, M. H. (2010) · International Journal of Diabetes Mellitus · doi:10.1016/j.ijdm.2010.05.006 · Cited by 7
SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus
Deshmukh, A. B., Patel, M. C., & Mishra, B. (2013) · Renal Failure · doi:10.3109/0886022x.2013.766560 · Cited by 8
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Brooks, A. D., Salvo, M. C., & Thacker, S. M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s59169 · Cited by 7
Effectiveness in the inhibition of dapagliflozin and canagliflozin on M-type K+ current and α-methylglucoside-induced current in pituitary tumor (GH3) and pheochromocytoma PC12 cells
So, E. C., Liu, P., & Wu, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173141 · Cited by 7
A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus
Huang, L., Cao, B., Geng, Y., Zhou, X., Yang, Y., Ma, T., Lin, H. Y., Huang, Z., Lang, Z., & Li, J. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106644 · Cited by 6
Bioequivalence Study and Bioanalytical Method Development of Remogliflozin etabonate tablets in wistar rat plasma using RP-HPLC Method
Tamilselvi, N., & Kanagapriya, K. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00122 · Cited by 6
Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits
Forouzanmehr, B., Hedayati, A. H., Gholami, E., Hemmati, M. A., Maleki, M., Butler, A. E., Jamialahmadi, T., Kesharwani, P., Yaribeygi, H., & Sahebkar, A. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111335 · Cited by 6
Dapagliflozin
Cada, D. J., Levien, T. L., & Baker, D. E. (2014) · Hospital Pharmacy · doi:10.1310/hpj4907-647 · Cited by 6
Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus
Zhang, H., Zhu, X., Li, X., Chen, H., Wu, M., Li, C., Liu, J., Liu, C., Zhang, Y., & Ding, Y. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13887 · Cited by 6
Dapagliflozin: where does it fit in the treatment of type 2 diabetes?
Woo, V. C. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903222281 · Cited by 6
A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors
Niazi, A. K., & Niazi, S. H. (2010) · North American Journal of Medical Sciences · doi:10.4297/najms.2010.2556 · Cited by 6
Glucose Reabsorption in The Kidney
Hummel, C. S., & Wright, E. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381462-3.00070-7 · Cited by 6
Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes
Sharma, S., Mittal, A., Kumar, S., & Mittal, A. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210917122745 · Cited by 5
Pregnancy-Associated Polyuria in Familial Renal Glycosuria
Toka, H. R., Yang, J., Zera, C., Duffield, J. S., Pollak, M. R., & Mount, D. B. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.05.018 · Cited by 5
Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor
Yokono, M., Tahara, A., Kurosaki, E., Yamajuku, D., Kihara, R., Imamura, M., Tomiyama, H., Kobayashi, Y., Noda, A., & Shibasaki, M. (2013) · Endocrine Research · doi:10.3109/07435800.2012.746364 · Cited by 5
Pharmacotherapy for obesity: a field in crisis?
Fenske, W. K., Parker, J., & Bloom, S. R. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 5
SYNTHESIS AND EVALUATION OF ANTIDIABETIC PROPERTIES OF A ZINC MIXED LIGAND COMPLEX IN HIGH-FAT DIET - LOW-DOSE STREPTOZOTOCIN-INDUCED DIABETIC RATS
Koothappan, M., Devi, V. R., Pillai, S. I., & Pillai, S. S. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i5.24870 · Cited by 5
Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus
Li, X., Zhu, X., Liu, J., Li, Q., Zhang, H., Li, C., Wu, M., Gao, L., Wen, H., Li, X., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14156 · Cited by 5
Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2, in patients with chronic kidney disease: A randomized trial
He, Y., Pachori, A. S., Chen, P., Ma, S., Mendonza, A. E., Amer, A., Marbury, T. C., & Hinder, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14327 · Cited by 5
Sodium–Glucose Co-transporter 2 Inhibition—A Novel Strategy for Glucose Control in Type 2 Diabetes
Norton, L., DeFronzo, R. A., Abdul‐Ghani, M. A., Instructor, & Chief, P. O. M. A. (2010) · US Endocrinology · doi:10.17925/use.2010.06.1.42 · Cited by 5

Authors: Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M.
Affiliations: Bristol-Myers Squibb (United States) (US)
Corresponding author: Pfister, M
ORCID: Pfister, M
Venue: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Published: 2009-01-07
Volume: 85
Issue: 5
Pages: 513-519
ISSN: 0009-9236 (ISSN-L)
1532-6535
DOI: 10.1038/clpt.2008.250
OpenAlex: W2000047428
Cited by: 396
References: 20
Citations by year: 2026: 14 · 2025: 13 · 2024: 16 · 2023: 14 · 2022: 16 · 2021: 17 · 2020: 14 · 2019: 22 · 2018: 18 · 2017: 19 · 2016: 24 · 2015: 18 · 2014: 39 · 2013: 39 · 2012: 32
FWCI: 27.68
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: dapagliflozin, SGLT2 inhibitors, type 2 diabetes, glycemic control, glycosuria, fasting serum glucose, oral glucose tolerance test, dose-dependent effects, urinary glucose excretion
MeSH terms: Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucose Tolerance Test, Glucosides, Glycosuria, Humans, Hypoglycemic Agents, Male, Middle Aged, Time Factors, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks